Background: Cancer treatment has many side effects; therefore, more efficient treatments are needed. Mesenchymal stem cells (MSC) have immunoregulatory properties, tumor site migration and can be genetically modified. Some proteins, such as soluble TRAIL (sTRAIL) and interleukin-12 (IL-12), have shown antitumoral potential, thus its combination in solid tumors could increase their activity. Materials and Methods: Lentiviral transduction of bone marrow MSC with green fluorescent protein (GFP) and transgenes (sTRAIL and IL-12) was confirmed by fluorescence microscopy and Western blot. Soluble TRAIL levels were quantified by ELISA. Lymphoma L5178Y cells express a reporter gene (GFP/mCherry), and TRAIL receptor (DR5). Results: An in vivo model showed that combined treatment with MSC expressing sTRAIL+IL-12 or IL-12 alone significantly reduced tumor volume and increased survival in BALB/c mice (p < 0.05) with only one application. However, at the histological level, only MSC expressing IL-12 reduced tumor cell infiltration significantly in the right gastrocnemius compared with the control group (p < 0.05). It presented less tissue dysplasia confirmed by fluorescence and hematoxylin–eosin dye; nevertheless, treatment not inhibited hepatic metastasis. Conclusions: MSC expressing IL-12, is or combination with BM-MSC expressing sTRAIL represents an antitumor strategy for lymphoma tumors since they increase survival and reduce tumor development. However, the combination did not show significative additive effect. The localized application did not inhibit metastasis but reduced morphological alterations of tissue associated with liver metastasis.

E14553 Background: Primary CNS lymphoma (PCNSL) is a rare malignancy, comprising only 2% of primary CNS tumors in the United States.While it’s incidence has decreased in the immunocompromised population (HIV positive) secondary to widespread access of effective anti-retroviral therapy, it is suspected that the rates are increasing among immunocompetent people aged 65+ years at a rate of approximately 1.7% per year. Data from the Surveillance, Epidemiology, and End Results (SEER) looking into survival and incidence patterns in PCNSL have a majority of non-Hispanic (NH) white population with lesser proportion of other ethnicities. Understanding racial and ethnic disparities on outcomes and patterns of care are crucial given the rapid growth of the Hispanic (HI) population in the US. Therefore, our study aims to compare survival outcomes and contributing factors in HI vs NH with PCNSL, who were treated at the only NCI designated Cancer Center in South Texas. Methods: This is a retrospective study, where we identified patients who were diagnosed and treated for PCNSL at UT Health San Antonio, between January 2008 and December 2018. The patient characteristics, treatment patterns, and clinical outcomes were listed as descriptive statistics. Results: From 2008-2018, a total of 29 patients with PCNSL were included. Among those, 62% were HI(Hispanic) and the remaining 38% were NH(Non-Hispanic). The median age at diagnosis was 61 years (58 years in HI and 70 years in NH). 55% were below 65 years and 45% were older than 65 years. Everyone received chemotherapy (89% received R-MPV (DeAngelis protocol) and 9% received other high dose methotrexate containing regimens). However, in terms of receiving Whole Brain Radiation Therapy (WBRT), the patients in the younger group were more likely to receive it than were those in the elderly group (68% versus 23% respectively). Overall Survival (OS) rate at 3 years was 41 % in HI and 33 % in NH (p = 0.08) and at 5 years was 41 % in HI and 25 % in NH (p = 0.03). Conclusions: While there is increasing data on higher incidence of non-HIV PCNSL in elderly population > 65 years, HI in our study population had a significantly lower median age at diagnosis with better survival and outcomes. Further studies on a larger patient population may help to describe the differences in incidence, tumor biology, genetics and outcomes in HI population.

E17612 Background: Prostate cancer is the most common cancer in men in the United States. Death in prostate cancer patients is often reported to be non-prostate cancer related, attributed to other medical conditions. As prostate cancer is associated with a prolonged survival, care of these patients includes optimizing other co-morbidities, such as cardiovascular disease. There are multiple reports and epidemiological studies of statins decreasing the risk, progression, and overall mortality of prostate cancer. Previously we had gathered data on 300 patients diagnosed with prostate cancer at the VA in San Antonio. The results indicated that using statins has a statistically significant positive effect at delaying death by prostate cancer, with a p-value of 0.018. We have updated our results with the addition of 105 patients. Methods: This is a retrospective observational study with chart review of 405 patients diagnosed with prostate cancer from 1995 to 2010, in a VA Hospital in San Antonio, Texas. Variables included age of diagnosis, statin use, type of statin (1st, 2nd, or 3rd generation), dose of statin (6 levels of dosage were identified), length of statin use, time followed in months (from time of diagnosis to either death or the end of the study period), death, and cause of death. The Cox proportional hazards regression model was used to estimate the hazard function, with age at diagnosis used as a covariate. Primary end point was death by prostate cancer (33 patients) and secondary end points- death by any cancer (71 patients), and death by all causes (205 patients). Results: The hazard ratio for use of statins at least 6 months was 0.56, with 95% confidence limits of 0.41 to 1.13, and a p-value of 0.118, indicating no statistically significant effect of statin usage and delay in death by prostate cancer. Secondary endpoint of death by all causes was significantly affected by statins, while death by any cancer showed no significant effect. The study was unable to conclude if the type of statin, dose of statin or the length of statin use had a significant effect in reaching the different end points. Conclusions: The addition of 105 more patients to this study has changed our previous statistically significant primary endpoint results.Concomitant statin use may not help prevent death from prostate cancer or death from any cancer, but may help prevent death from all causes. This updated primary endpoint data conflicts with multiple prior epidemiological studies and raises questions on the impact of statin usage on men with prostate cancer.

E20083 Background: Non-Hodgkin Lymphoma (NHL) continues to be in the top 10 of all cancer related deaths. Discrepancies exist among world regions in lymphoma subtype incidence, with a percentage of DLBCL being higher in Latin America versus Nordic countries. T cell lymphomas (TCL) are reported to be more common in east Asia than in the Western hemisphere.The geographic differences in distribution along with under representation of ethnic minorities across all lymphoma subtypes, establish the basis of our analysis at the only NCI-designated cancer center within a Hispanic (H) predominant patient population. We aim to describe our population diagnosed with Hodgkin Lymphoma (HL) and NHL and compare to known overall global and USA statistics. Methods: Observational study, retrospectively analyzed patients with diagnosis of Lymphoma (HL and NHL). The patients received care at UT Health San Antonio, the biggest Hispanic serving Academic Institution in South Texas, between 2008-2018. Key variables included age, gender, race/ethnicity, stage, treatment received, vitality at 3 and 5 years. Continuously distributed outcomes were summarized with the mean and standard deviation and categorical outcomes were summarized with frequencies and percentages. Primary end point was to characterize distribution of HL and NHL by subtypes in our Cancer Center and compare to North American and overall global distribution. Results: A total of 685 patients with lymphoma were identified. Of the NHL subtypes; DLBCL was the most common identified (209, 31%), (FL) was the most common indolent lymphoma (IL) among all demographic groups (123, 26%), followed by HL (116, 17%) which was more common among non-Hispanic (NH) subgroup (73, 63% vs 42, 36%). Among the TCL, CTCL – Mycosis fungoides was the most common subtype (18, 35%) followed by ALK negative ALCL (12, 24%). Incidence by Gender: The percentage of males (M) was slightly higher vs. females (F) in all subtype lymphoma diagnoses, M (352, 51%), F (333, 49%). M had a higher incidence in DLBCL (108, 52% vs 101, 48%), BL (9, 69% vs 4, 31%), and HL (67, 58% vs 49, 44%). Incidence by Race: Total lymphoid neoplasm rates were higher for H (383, 57%) than NH (293, 43%), other (1, 0.2%), not specified (5, 1%). H had a higher incidence in all subtype lymphomas except for Nodular lymphocyte predominant HL (5, 63% vs 3, 37%). Conclusions: Our Hispanic Hispanic Serving Academic Institution, the distribution of lymphomas doesn’t change when compared with previous reported data. Our population and distribution of lymphoma subtypes are similar to global and USA data.